Oncolytics Biotech’s Cancer Drug Aims for Fast-Track Approval
Company Announcements

Oncolytics Biotech’s Cancer Drug Aims for Fast-Track Approval

Story Highlights
  • Oncolytics Biotech advances towards accelerated FDA approval for breast cancer therapy.
  • Global cancer rates are surging, with significant increases in both new cases and projected future rates.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Oncolytics Biotech (TSE:ONC) has released an update.

Oncolytics Biotech Inc. is making significant strides in cancer treatment, with the FDA potentially accelerating approval of their breast cancer therapy, pelareorep. This development comes amid a global rise in cancer rates, with a 79% increase in new cases and a projected 77% increase by 2050. The company’s BRACELET-1 trial results are promising, setting the stage for a large study targeting HR+/HER2- metastatic breast cancer patients.

For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskOncolytics Biotech Reports Promising Cancer Treatment Results
TheFlyOncolytics reports Q3 EPS (12c), consensus (7c)
TipRanks Canadian Auto-Generated NewsdeskOncolytics Biotech Announces Q3 Results Conference
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App